<p>The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.</p>

Subscribe

Title Date published
Biotech Story Time With Tal Zaks, M.D. (Part 2, Tall Tales with Tal) 2025-01-06
Risk Mitigation With Meira GTx's Zandy Forbes, Ph.D. 2024-12-30
Biotech Story Time With Tal Zaks, M.D. (Part 1) 2024-12-23
A $1B AI Bet With Foresite Labs' Vik Bajaj, Ph.D. 2024-12-16
Manufacturing Partnership With Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski 2024-12-09
Novel Peptide Delivery With Revolo's Woody Bryan, Ph.D. 2024-12-02
Biopolitics With Allan Shaw 2024-11-25
T-Cells For The Win With Adaptimmune's Adrian Rawcliffe 2024-11-18
Serving The Underserved With Gates MRI's Claire Wagner, M.D. 2024-11-11
An Unanticipated Biotech Startup With OS Therapies' Paul Romness 2024-11-04
Building On Pandemic Progress With Barinthus Biotherapeutics' Bill Enright 2024-10-28
Obesity Tx End-Around With Skye Bioscience's Punit Dhillon 2024-10-21
Biotech C-Suite Construction With Allan Shaw 2024-10-14
The Peptide Promise With NervGen's Mike Kelly 2024-10-07
Biotech Course Correction With Treehill Partners' Ali Pashazadeh 2024-09-30
An AI Awakening With Profluent Bio's Hilary Eaton, Ph.D. 2024-09-23
Picking Biotech Jockeys With SR One's Simeon George, M.D. 2024-09-16
Embracing Biotech Chaos With Memo's Erik van den Berg 2024-09-09
Pivoting To RNA With Circio's Dr. Erik Digman Wiklund 2024-09-02
mRNA Upstarts With Radar Therapeutics' Sophia Lugo and Eerik Kaseniit, Ph.D. 2024-08-26
1234567891011121314

Comments about Business Of Biotech

comments powered by Disqus
Advertisment: